Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.

Mafalda C RamosPeng MenXu WangAnastasia UstyugovaMark Lamotte

Published in: Cost effectiveness and resource allocation : C/E (2021)

Results suggest that empagliflozin + SoC is cost-effective compared to sitagliptin + SoC and liraglutide + SoC at a willingness-to-pay threshold of 212,676RMB ($30,292)/QALY.

Keyphrases

cardiovascular disease
type diabetes
health insurance
cardiovascular risk factors
metabolic syndrome
cardiovascular events